Center for International Blood and Marrow Transplant Research
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Center for International Blood and Marrow Transplant Research sits in the top decile of US sponsors by registered trial count (#553 of 15,742 sponsors by registered trial count).
Center for International Blood and Marrow Transplant Research: 29 sponsored US clinical trials, 7 recruiting.
Center for International Blood and Marrow Transplant Research sponsors 29 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 15 completed. 1 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelodysplastic Syndromes, with 3 trials.
Top-decile sponsor footprint
Center for International Blood and Marrow Transplant Research ranks in the top decile of sponsors by registered trial count (#553 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
29 total, page 1 of 1
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT06859424
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
NCT02934477
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
CIBMTR Research Database
NCT01166009
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
NCT00785525
Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
NCT04920474
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
NCT05224661
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT04904588
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
NCT03971799
Conditioning SCID Infants Diagnosed Early
NCT03619551
Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)
NCT03992352
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
NCT03904134
Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors
NCT03718546
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
NCT03558386
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
NCT02793544
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
NCT02338050
Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors
NCT02200133
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
NCT01772953
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
NCT01696461
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
NCT01385787
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
NCT01353677
National Marrow Donor Program Long-Term Donor Follow-Up
NCT01362179
Stem Cell Related Donor Safety Study
NCT00948636
The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family
NCT00795054
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
NCT00847639
Adult Double Cord Blood Transplant Study
NCT00514579
Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma
NCT00318110
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 11 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Center for International Blood and Marrow Transplant Research pipeline
7 recruiting of 29 indexed (24% open); 15 completed (52%).
Phase mix: 1 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Myelodysplastic Syndromes (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Center for International Blood and Marrow Transplant Research: open-pipeline peers nationwide
Peers matched on 29 registered trials and 24% open enrollment, not the therapeutic-area sidebar.
Center for International Blood and Marrow Transplant Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 29 trials (± recruiting share)
- BeOne Medicines · 29 trials · 79% recruiting
- BioCryst Pharmaceuticals · 29 trials · 7% recruiting
- California Pacific Medical Center Research Institute · 29 trials · 10% recruiting
- Craig Hospital · 29 trials · 21% recruiting
Sponsors near 24% open enrollment (± trial volume)
- AdventHealth Translational Research Institute · 24% recruiting · 54 trials
- Auburn University · 24% recruiting · 54 trials
- Genmab · 24% recruiting · 45 trials
- Boston Children's Hospital · 24% recruiting · 462 trials
Related
What to do with this Center for International Blood and Marrow Transplant Research page
29 registered trials is a research-attention snapshot, not an endorsement of Center for International Blood and Marrow Transplant Research or any single study.
- 7 of Center for International Blood and Marrow Transplant Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Myelodysplastic Syndromes is the condition Center for International Blood and Marrow Transplant Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelodysplastic Syndromes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Center for International Blood and Marrow Transplant Research pipeline card: 29 registered trials from official public datasets.Report a data error.